Law360, New York (January 19, 2007, 12:00 AM ET) -- To maintain competition in the generic injectable drug market, the U.S. Federal Trade Commission said Thursday that Hospira Inc. has to sell five drugs to acquire rival drug maker Mayne Pharma Ltd.
The FTC said that without the divestiture, the $2 billion deal would violate U.S. competition laws.
“Just as with generic oral pharmaceutical products, consumers benefit from robust competition in the markets for generic injectable drugs,” said Jeffrey Schmidt, director of the FTC’s Bureau of Competition. “The order requiring the divestiture of the five drugs...
Antitrust Watchdog Forces Drug Divestitures
To view the full article, take a free trial now.
